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The molecular events mediating the immunomodulatory properties of cannabinoids have remained largely unresolved. We have therefore
investigated the molecular mechanism(s) through which R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl] pyrrolo[1,2,3-de]-1,4-benzox-
azinyl]-(1-napthanlenyl) methanone (WIN55212-2) modulate production of interleukin-8 (IL-8) in HT-29 cells. Release of IL-8 induced by tumor
necrosis factor-α (TNF-α) was determined by enzyme-linked immunosorbent assay (ELISA). Changes in expression of inhibitory kappa B (IκB)
were monitored by Western blotting and activation of nuclear factor-kappa B (NF-κB) was determined in electrophoretic mobility shift assay
(EMSAs). TNF-α induced release of IL-8 was inhibited by WIN55212-2 which also blocked the degradation of IκB-α and activation of NF-κB
induced by TNF-α. These data provide strong evidence that WIN55212-2 may modulate IL-8 release by negatively regulating the signaling
cascade leading to the activation of NF-κB. These findings highlight a potential mechanism for the immunomodulatory properties of cannabinoids
and contribute towards acquiring a clear understanding of the role of cannabinoids in inflammation.
© 2006 Elsevier B.V. All rights reserved.Keywords: WIN55212-2 [methanone mesylate]; IL-8 [interleukin-8]; IκB [inhibitory kappa B]; NF-κB [nuclear factor-kappa B]; cannabinoid; CB2 receptor; HT-291. Introduction
Pro-inflammatory cytokines are pivotal for the development
of an inflammatory response and therefore constitute a
pharmacological target for the development of anti-inflamma-
tory therapies. In particular, the chemoattractant cytokine
interleukin-8 (IL-8; now referred to as CXCL8) is essential
for the recruitment of immune cells to the site of inflammation
and for a coordinated immune response (Miller and Krangel,
1992; Baggiolini et al., 1997).
Because of their immunomodulatory properties, therapeutic
use of cannabinoids could provide new approaches for the
development of anti-inflammatory therapies. However, although
many immunosuppressive as well as some immunostimulatory
effects are documented (Croxford and Yamamura, 2005), and
cannabinoids historically have been used as anti-inflammatory
agents, the molecular mechanisms underlying these effects are
poorly understood. Cannabinoids may however modulate
immune responses by regulating the cytokine system (Klein et
al., 1998), and this may be due in part to their ability to regulate⁎ Corresponding author. Tel.: +44 1707 285 120; fax: +44 1707 285 046.
E-mail address: a.baydoun@herts.ac.uk (A.R. Baydoun).
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and subsequent expression of immune cytokines. In this regard,
cannabinoids have been reported to down regulate the adenylate
cyclase (AC) cascade, which is thought to be the main signal
transduction pathway implicated in the immune response (Schatz
et al., 1992; Diaz et al., 1993; Kaminski et al., 1994; Kaminski,
1998). Inhibition of AC and thus of cAMP production may
consequently inhibit protein kinase A (PKA), and hence
phosphorylation of several downstream targets including the
cAMP-response element binding protein/activation transcription
factor (CREB/ATF) and NF-κB (Herring et al., 1998; Herring and
Kaminski, 1999), thus suppressing the inflammatory process.
Epithelial cells are an important component of the mucosal
immune system, performing a variety of immune functions,
including the expression of adhesion molecules and the secretion
of cytokines (Schuerer-Maly et al., 1994). This central role and
their proximity to the intestinal lumen make these cells easily
accessible to pharmacological agents, and modulation of their
activities is of major therapeutic importance in inflammation. In
this report, we have therefore used the human HT-29 colon
epithelial cell line to examine the molecular mechanism by which
cannabinoids may regulate cytokine release. The studies have
focused on the potent cannabinoid CB1/CB2 receptor agonist R-
Fig. 3. Time course of TNF-α induced IκB degradation in HT-29 cells.
Confluent monolayers of cells were stimulated with TNF-α (100 ng/ml) at 37 °C
for the indicated times. Levels of IκBwere determined byWestern blotting using
a specific monoclonal antibody as described in methods. The blot is
representative of three separate experiments.
Fig. 1. TNF-α induced release of IL-8 from HT-29 cells. Confluent monolayers
of cells were stimulated with increasing concentrations of TNF-α (10–1000 ng/
ml) for 24 h. IL-8 release was measured by ELISA as described in methods.
Data represent means±S.E.M. of three separate experiments. ⁎P<0.01.
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de]-1,4-benzoxazinyl]-(1-napthanlenyl) methanone mesylate
(WIN55212-2) which has previously been shown to inhibited
tumor necrosis factor-α (TNF-α) induced release of IL-8 via an
action on the cannabinoid CB2 receptors. The latter conclusion
was based partly on functional studies where WIN55212-2
induced inhibition of IL-8 release was reversed by the
cannabinoid CB2 receptor antagonist [N-[(1S)-endo-1,3,3,-tri-
methyl-bicyclo[2,2,1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-
1-(4-methylbenzyl)-pyrazole-3-carboxamide] (SR144528), but
not by the CB1 receptor antagonist [N-(piperidin-1-yl)-5-(4-
chlorophenyl)-1-(2,4-dichlorphenyl)-4-methyl-H-pyrazole-3 car-
boxyamidehydrochloride] (SR141716A) and partly on data
from Western blot analysis using a polyclonal antibody raised
against the amino terminus of the cannabinoid CB2 receptor
(Ihenetu et al., 2003a).
Since IL-8 release may require de novo synthesis and thus
gene transcription, our studies have focused on establishing
whether NF-κB may be involved in this process and, more
importantly, whether cannabinoids may be able to modulate IL-
8 release through regulation of the activity of this ubiquitous
transcription factor which has been shown to play a crucial role
in mediating cytokine-induced gene expression (Tak and
Firestein, 2001). In light of current trends in cannabinoid
research, addressing the transcriptional component of this
process may contribute towards acquiring a clear and valuableFig. 2. Effect of MG132, actinomycin D and cycloheximide on TNF-α induced
IL-8 release in HT-29 cells. Confluent monolayers of cells were treated with
either MG132 (3 μM), actinomycin D (10 μM) or cycloheximmide (10 μM) for
30 min prior to stimulation with TNF-α (100 ng/ml) for 24 h. Data are expressed
as percentage of inhibition with respect to the TNF-α activated controls and
represent means±S.E.M. of three separate experiments.understanding of the inflammatory process as well as of the role
of cannabinoids and cannabinoid receptors in the function of the
immune system. The elucidation of such complex events may
lead ultimately to new therapeutic approaches that take
advantage of an intersection not yet fully exploited.
2. Materials and methods
2.1. Drugs and reagents
Tissue culture reagents were obtained from Gibco (Paisley,
UK). Other reagents used were: WIN55212-2 (Tocris Cookson,
Bristol, UK); TNF-α (PeproTech, Ltd, London, UK); Z-Leu-
Leu-Leu-CHO (MG132; Calbiochem, Beeston, Nottingham,
UK) and [γ32P]dATP (Amersham, UK). 3-(4,5-dimethylthia-
zole-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT), aprotinin,
benzamidin, chymostatin, leupeptin, pepstatin, phenylmethyl-
sulfonyl fluoride (PMSF), dithiothreitol (DTT), sodium
vanadate, actinomycin D and cycloheximide were purchased
from Sigma-Aldrich (Pool, UK). The IκB-α rabbit affinity
purified polyclonal antibody and anti-rabbit immunoglobulin
G-horseradish peroxidase (IgG-HRP) conjugated secondary
antibody were from Biotechnology, UK. Biotinylated mouse
anti-human IL-8 monoclonal antibody, streptavidin-HRP
conjugate secondary antibody, tetramethylammonium-benzi-
dine (TMB) and 96-well Nunc-immunoplates (maxisorpF96)
for ELISA detection were from Pharmingen BD (Oxford, UK).
DNA oligomers containing the NF-κB (GGG GAC TTT CCC)
consensus sequences were purchased from Promega (South-
ampton, UK). All other drugs and chemicals were obtained
from Sigma or BDH and were of the highest analytical grade
obtainable.
2.2. Cell culture
The HT-29 colon epithelial cell line was obtained from the
European Collection of Animal Cell Cultures (ECACC,Fig. 4. Time course of TNF-α induced NF-κB activation in HT-29 cells. Nuclear
extracts (10 μg per lane) were prepared from cells treated with TNF-α (100 ng/
ml) as described in methods. Nuclear proteins were probed in EMSAs with 32P
labeled κB oligomer and autoradiographed. The blot is representative of three
separate experiments. CC: extract from cold competition with unlabelled probe;
C: extract from control non-activated cells.
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McCoy's 5A medium supplemented with 10% foetal bovine
serum and penicillin/streptomycin (50U/ml and 50 μg/ml
respectively) plus amphotericin B (0.5 μg/ml). Cultures were
maintained in 75 cm2 culture flasks at 37 °C in a 5% CO2
humidified tissue culture incubator.
2.3. Plating of cells for experimentation
Confluent monolayers were subdivided and plated at a
density of 5×105 cells/ml in T75 tissue culture flasks. To detach
the monolayer from the flasks, cells were washed once with
sterile phosphate buffered saline (PBS) and incubated for
approximately 5 min in the presence of 0.25% trypsin/ethylene
diamine tetracetic acid (EDTA). Once detached, the action of
trypsin was stopped by adding 5 ml of McCoy's 5A containing
10% foetal bovine serum. Cells were diluted to the appropriate
density, plated and incubated as described.
Prior to each experiment cells were washed twice with warm
sterile PBS and the incubation medium replaced with fresh
serum-free McCoy's medium. All experiments were carried out
in the absence of serum.
2.4. Enzyme linked immunosorbent assay for IL-8 release
TNF-α-induced IL-8 release from HT-29 cells was
determined by ELISA. Confluent cells grown in 24-well plates
as described above were pre-incubated in the presence of
appropriate drugs for varying time periods depending on the
experimental protocol. Cells were then activated with TNF-α
(100 ng/ml) for 24 h. At the end of the incubation time
supernatants were collected and stored at −20 °C until the
assay was performed. 96-well Nunc-immunoplates were
coated overnight with 1 μg/ml anti-human IL-8 monoclonal
capture antibody. Plates were subsequently washed three times
with washing buffer (phosphate buffered saline plus 0.05%
Tween 20) and blocked with assay diluent (phosphate buffered
saline plus 10% foetal bovine serum) for 1 h at room
temperature. After three washes, standards and samples
(supernatants diluted 1/10 in serum-free medium) were added
and incubated at room temperature for 2 h. Standard and
samples were discarded and plates were washed five times
with washing buffer. Detection was performed in a single step
by incubating the plates in the presence of a biotinylated anti-
human IL-8 antibody and streptavidin linked peroxidase
conjugate (each at 0.5 μg/ml respectively). After incubation
for 1 h plates were washed seven times and TMB was used as
a substrate to quantify the amount of bound conjugate by
colorimetric measurement. Absorbance was read at a wave-
length of 450 nm using a Multiskan II plate reader and the
values obtained converted using an IL-8 standard curve
constructed in parallel.
2.5. Western blot analysis of IκB-α expression
Lysates for Western blot analysis were prepared from cells
following various experimental conditions. Protein concentra-tions were determined using bicinchoninic acid (BCA) reagents
according to the instructions provided by the manufacturer.
Western blotting was carried out as described by Cirino et al.
(1996). Briefly, 2 μl of 2% bromophenol blue and 5 μl of stock
β-mercaptoethanol were added to the samples and heated at
95 °C prior to loading 20 μg of protein onto a sodium dodecyl
sulfate (SDS)-polyacrylamide gel (8%). After separation,
proteins were transferred for 2 h at 0.8 mA cm−2 onto a
polyvinyldene difluoride (PVDF) membrane (Amersham, UK).
Membranes were blocked for 1 h at 37° in 10 mM Tris, 100 mM
NaCl, 0.1% (v/v) Tween-20 (STT) buffer (pH 7.4) containing
5% (w/v) of dry non-fat milk and incubated with a polyclonal
anti-IκB-α antibody for a further 1 h at 37 °C. This was
followed by 3 washes with STT buffer prior to incubating with a
secondary anti-rabbit polyclonal IgG conjugated with horse-
radish peroxidase (dilution 1:5000 in STT buffer containing 5%
(w/v) dry non-fat milk). Membranes were subsequently washed
with STT buffer and the immunoreactive bands visualized using
the enhanced chemiluminescence detection system.
2.6. Electromobility shift assay (EMSA)
Changes in the activation of NF-κB under different
experimental conditions were determined by electromobility
shift assays (EMSAs). Confluent HT-29 monolayers in T75
tissue cultures flasks were treated as required. Cells were then
washed with ice-cold PBS and lysed in 1 ml of lysis buffer
consisting of: Tris–HCl (10 mM, pH 7.5), MgCl2 (1.5 mM),
KCl (10 mM) and NP-40 (0.5%) supplemented with 1.5 μg/ml
of aprotinin, benzamidine, chymostatin, leupeptin and pepsta-
tin, plus phenylmethylsulphonylfluoride (PMSF; 0.2 mM),
DTT (0.5 mM) and sodium vanadate (10 μM). Lysates were
transferred into 1.5 ml eppendorff tubes and centrifuged at 4 °C
for 5 min at 3290 ×g. Nuclear fractions were subsequently
treated with 0.5 ml of the above lysis buffer. The lysate was
centrifuged at 4 °C for 5 min at 3290 ×g and the supernatant
discarded. The nuclear pellet was further lysed in 50 μl buffer
containing Tris–HCl (20 mM, pH 7.5), MgCl2 (1.5 mM), NaCl
(420 mM), EDTA (0.2 mM), Glycerol (10%) plus the cocktail
of protease inhibitors described above. After incubation on a
platform rotator for 45 min lysates were centrifuged at 13147 ×g
for 15 min at 4 °C and the supernatants diluted in 50 μl buffer
containing Tris–HCl (20 mM, pH 7.5), MgCl2 (1.5 mM), EDTA
(0.2 mM), Glycerol (10%) plus the cocktail of protease
inhibitors. Samples were stored at −80 °C for subsequent use
in EMSAs.
DNA oligomer containing the NF-κB (GGG GAC TTT
CCC) consensus sequence was end-labeled with [γ32P]dATP.
Typically, 10 μCi radioactive nucleotide (1 μl of 10 mCi/ml)
was used to label 3.5 pM of oligonucleotide (2 μl of 1.75 pmol/
μl stock) by incubation at 37 °C in the presence of 1 μl of T4
polynucleotide kinase (T4 PNK) in 1 μl of 10× T4
Polynucleotide Kinase Buffer (Tris–HCl (pH 7.6, 700 mM),
MgCl2 (100 mM) and DTT (50 mM)). The final volume was
made up to 10 μl with 5 μl autoclaved H2O. Nuclear extracts
(10 μg) were incubated with 1 μl of the labeled probe in 2 μl of
binding buffer (20% glycerol, 5 mM MgCl2, 2.5 mM EDTA,
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0.25 mg/ml poly(dI-dC)•poly(dI-dC)) for 40 min on ice.
Samples were subsequently mixed with 1 μl of 10× loading
buffer (250 mM Tris–HCl (pH 7.5), 0.2% bromophenol blue
and 40% glycerol) before loading onto a 4% acrylamide non-
denaturing gels and run at 130 V for 2 h. Gels were dried and
autoradiographed for analysis.
2.7. Cell viability assay
Cells in 96-well plates were treated under corresponding
experimental conditions and incubated with 100 μg MTT for
2 h at 37 °C, 5% CO2, in standard culture medium. The medium
was subsequently aspirated and purple formazan crystals
solubilised in 100 μl of isopropanol. The extent of reduction
of MTT to formazan within cells was quantified by measure-
ment of OD550 using a Multiskan II plate reader.
2.8. Statistical analysis
Unless specified, all results are expressed as percentage of
IL-8 released by TNF-α (100 ng/ml) treated cells and are the
mean±S.E.M. of at least 3 separate experiments. Statistical
significance was calculated by analysis of variance (ANOVA)
followed by Dunnett's post hoc test. Differences were taken to
be statistically significant when P<0.05.
3. Results
3.1. TNF-α dependent up-regulation of IL-8 release
Previous studies have shown that unstimulated HT-29 cells
express low basal levels of IL-8 which can be increased in a
time-dependent manner following stimulation of cells (Ihenetu
et al., 2003a). Consistent with this observation, our initial
studies confirm that treatment of HT-29 cells with TNF-α (10–
1000 ng/ml) for 24 h results in a concentration-dependent
increase in the levels of IL-8 released into the culture medium
(Fig. 1). At the submaximal concentration of 100 ng/ml, TNF-α
significantly increased IL-8 release from a basal value of 890±
91 pg/ml to 12250±147 pg/ml (P<0.05). This concentration
was therefore used in all subsequent experiments to avoid using
high cytotoxic concentrations of this cytokine which may be
observed following prolonged incubations with 1000 ng/ml.
3.2. Effects of MG132, cycloheximide and actinomycin D on
TNF-α-induced IL-8 release
In order to establish whether the stimulatory effects of TNF-
α on IL-8 release was due to the activation of NF-κB, induced
gene transcription and de novo protein synthesis, experiments
were carried out examining the effects of the proteasomal
inhibitor MG132, the inhibitor of gene transcription actinomy-
cin D and the protein synthesis inhibitor cycloheximide on
TNF-α induced IL-8 release. In these studies, cells were pre-
treated with each drug for 30 min prior to stimulation with TNF-
α. The data obtained (Fig. 2) show that TNF-α induced IL-8 release was significantly attenuated by MG132 (3 μM),
actinomycin D (10 μM) and by cycloheximide (10 μM) which
respectively inhibited IL-8 release by 76±0.7%, 95±3% and
80±1.6%.
3.3. Degradation of IκB-α and activation of NF-κB by TNF-α
The data with MG132 strongly suggests that activation of
NF-κB by TNF-α may be critical for the induction of IL-
8 release. To substantiate this hypothesis, additional experi-
ments were carried out examining the effects of TNF-α on both
IκB-α degradation and on NF-κB-DNA binding activity.
Treatment of HT-29 cells with TNF-α (100 ng/ml) resulted in
a time-dependent reduction in IκB-α protein which was evident
after 10 min, reaching a maximum at 15 min and staying at this
depleted level over 30 min before returning to pre-stimulated
basal levels after 1 h (Fig. 3).
In parallel studies, NF-κB-DNA binding was found to be
minimal in nuclear extracts from control cells but increased after
10 min of exposure to TNF-α and remained at this elevated
level for up to 1 h after activation. This increase in NF-κB-DNA
binding was significantly inhibited by a 10-fold excess of
unlabelled NF-κB-specific oligonucleotide indicating the spec-
ificity of binding (Fig. 4).
3.4. Effects of the cannabinoid receptor agonist WIN55212-2
on TNF-α induced IL-8 release
To confirm that cannabinoids regulate IL-8 release, HT-29
cells were pre-incubated with the potent cannabinoid CB1/CB2
receptor agonist WIN55212-2 (10−10 to 10−4 M) for 2 h prior to
activation with TNF-α (100 ng/ml)? for 24 h. As shown in Fig.
5, WIN55212-2 exerted a concentration-related inhibition of
TNF-α induced secretion of IL-8, completely abolishing the
latter at 10−5 M and inhibiting by approximately 70% at
10−6 M (P<0.01, n=6).
In parallel experiments, addition of WIN55212-2 (10−6 M)
either simultaneously with or at different intervals after
activation of cells with TNF-α (100 ng/ml) failed to cause
any significant change in TNF-α-induced IL-8 release. In these
studies, levels of IL-8 remained unaltered with respect to the
control TNF-α activated cells (Fig. 6).
3.5. Effects of WIN55212-2 on TNF-α induced NF-κB
activation and IκB-α degradation
Effects of WIN55212-2 on the activation of NF-κB was
examined in samples prepared from cells pretreated for 2 h with
increasing concentrations of WIN55212-2 (10−9 to 10−4 M)
prior to activation with TNF-α (100 ng/ml) for 1 h. In these
series of experiments, there were very little detectable NF-κB–
DNA complexes formed by nuclear extract from control non-
activated cells. In contrast, incubation of nuclear extracts from
TNF-α activated cultures with the 32P labeled κB oligonucle-
otide exhibited increased DNA binding activity which, as
shown previously in Fig. 4, was virtually abolished by a 10-fold
excess of unlabelled NF-κB-specific oligonucleotide. More
Fig. 7. Effect of WIN55212-2 on TNF-α induced NF-κB activation in HT-29
cells. Nuclear extracts were prepared from confluent cultures pre-treated for 2 h
with WIN55212-2 prior to activation with TNF-α (100 ng/ml) for 1 h. Nuclear
proteins were probed with 32P labeled κB oligomer and autoradiographed. C:
non-activated control; A: TNF-α activated control. The blot is representative of
three separate experiments.
Fig. 5. Effect of WIN55212-2 on TNF-α induced IL-8 release in HT-29 cells.
Confluent monolayers of cells were incubated for 2 h in the presence of
increasing concentrations of WIN55212-2 prior to stimulation with TNF-α
(100 ng/ml) for 24 h. IL-8 release was measured by ELISA as described in
methods. Data represent means±S.E.M. of six separate experiments. ⁎P<0.01.
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duced NF-κB–DNA binding, virtually abolishing the latter at
10−5 M. A significant inhibition was also observed with
10−6 M WIN55212-2 with lower concentrations (≤10−7 M)
having little or no effect (Fig. 7). In parallel with the changes in
NF-κB–DNA binding activity, TNF-α-induced degradation of
IκB-α was also inhibited in a concentration-dependent manner
by WIN55212-2. As shown in Fig. 8, WIN55212-2 completely
restored IκB-α protein expression back to basal levels at
10−5 M with 10−6 M showing partial inhibition of the
degradation of IκB.
4. Discussion
The molecular mechanisms by which cannabinoids exert
their broad range of biological effects have still not been fully
elucidated. One key area of progress in this field is the common
understanding that regulation of adenylate cyclase may be
critical for cannabinoid-mediated immunosuppression (Schatz
et al., 1992; Diaz et al., 1993; Kaminski et al., 1994; Kaminski,
1998). Although, the precise role of cAMP signaling in immuneFig. 6. Effect of WIN55212-2 on IL-8 release in TNF-α pre-stimulated HT-29
cells. Confluents monolayers of cells were activated with TNF-α (100 ng/ml)
and WIN55212-2 (10−6M) added at the time points indicated post-activation.
Supernatants were collected 24 h after TNF-α activation and analyzed by ELISA
for IL-8. Data represent means±S.E.M. of three separate experiments.regulation is still not well defined, there are indications that this
may occur via down regulation of protein kinase A (PKA)
through inhibition of cAMP production which may in turn
suppress binding of CREB/ATF transcription factors to the
cAMP response element (CRE) consensus motif (Koh et al.,
1997; Herring et al., 1998; Herring and Kaminski, 1999).
Additionally, cannabinoids acting in part through suppression
of PKA may inhibit activation of NF-kB (Jeon et al., 1996;
Herring et al., 1998; Herring and Kaminski, 1999). It is worth
noting however that these actions may be cannabinoid and/or
cell specific since in mouse thymocytes, cannabinol-induced
inhibitions of CREB/ATF-1 phosphorylation and NF-κB–DNA
binding activity could not be reversed by the membrane
permeable analogue of cAMP, dibutyryl cAMP (DBcAMP), nor
by the potent PKA inhibitor N-(2-[p-bromocinnamylamino]
ethyl)-5-isoquinolinesulfonamide (H89; Herring et al., 2001).
Moreover, in mast cells, CB1 ligands cause an accumulation
rather than inhibition in cytosolic cAMP levels (Small-Howard
et al., 2005) while in mouse dendritic cells, exposure to Δ9-
tetrahydrocannabinol (Δ9-THC) induced phosphorylation of
IκB-α and enhanced NF-κB activation (Do et al., 2004).
Despite the vast literature on the immunosuppressive actions
of cannabinoids, there is currently little data on the molecular
mechanisms that may account for the actions of these
compounds in modulating IL-8 release by other pro-inflamma-
tory mediators. Attempts were therefore made in the current
studies to elucidate the molecular mechanism responsible for
the suppression of TNF-α-induced IL-8 release by WIN55212-
2 in the human colon epithelial cell line HT-29. Stimulation of
these cells with TNF-α for 24 h caused a concentration-
dependent increase in IL-8 production which was significantly
inhibited by WIN55212-2. This finding is consistent with the
inhibition by WIN55212-2 of IL-8 release in human astrocytesFig. 8. Effect of WIN55212-2 on TNF-α induced IκB degradation in HT-29
cells. Cell lysates were prepared from cultures pre-treated with WIN55212-2 for
2 h prior to activation with TNF-α (100 ng/ml) for 30 min. Levels of IκB were
determined by Western blotting using a specific monoclonal antibody as
described in methods. C: non-activated control; A: TNF-α activated control. The
blot is representative of three separate experiments.
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that demonstrated the greater efficacy of WIN55212-2 over
other cannabinoid receptor agonists in suppressing TNF-α
induced IL-8 release in HT-29 cells (Ihenetu et al., 2003a).
Interestingly, the above data contrast with reports in the
promyelocytic cell line HL60 where (−)-cis-3-[2-hydroxy-4-
(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclo-
hexanol (CP-55940; Jbilo et al., 1999; Kishimoto et al., 2004)
and 2-Arachidonoylglycerol (Kishimoto et al., 2004) were
shown to enhance IL-8 mRNA and protein expression in a CB2
dependent manner. The precise reasons for these paradoxical
actions of different cannabinoids on IL-8 release are unclear and
may be governed by several factors, including the cannabinoid
in question; the cell types used and even the status of the cells
being experimented upon. In this context, it has been reported
that cannabinol may induced IL-2 production in partially
activated T-cells but decrease the same process when the cells
are optimally activated (Jan and Kamanski, 2001). This
highlights the complex nature of the cellular actions of
cannabinoids and may warrant caution in interpreting results
from one system to the next. It is important to emphasising
however that the immunosuppressive action of WIN55212-2 is
a widely reported phenomenon which is not restricted to the
inhibition of IL-8 alone. WIN55212-2 has also been shown to
reduce LPS-induced TNF-α production in human peripheral
blood mononuclear cells (Germain et al., 2002), rat cortical
microglial cells (Facchinetti et al., 2003), bronchoalveolar
lavage fluid (Berdyshev et al., 1998), and inhibits interleukin-2
(IL-2) release from human peripheral blood mononuclear cells
(Ihenetu et al., 2003b) and from mouse splenocytes (Kaplan et
al., 2003). Moreover, such actions are common with other
cannabinoids including Δ9-THC, which like WIN55212-2 also
suppressed LPS-induced TNF-α levels in bronchopulmonary
inflammation in mice (Berdyshev et al., 1998) and reduced
LPS-induced mRNAs for IL-1 and TNF-α in neonatal rat
microglial cells (Puffenbarger et al., 2000). Similarly, suppres-
sion of IL-2 release has been reported with anandamide
(Rockwell and Kaminski, 2004), cannabinol (Herring and
Kaminski, 1999; Herring et al., 2001) and 2-arachidonyl-
glycerol (Ouyang et al., 1998).
The inhibitory effects of WIN55212-2 in our studies were
critically dependent on the time of addition of the compound
prior to activation of cells. Maximal effects were observed when
WIN55212-2 was added before TNF-α and allowed to
equilibrate with cells before they were being activated. In
contrast, application of WIN55121-2 together with or up to 9 h
after TNF-α failed to cause any significant change in induced
IL-8 production. This may be due to the combination of a slow
action of WIN55212-2 and a quick activation by TNF-α of the
NF-κB signaling cascade. It is possible that in this case,
WIN55212-2 may be acting through mechanisms that trigger
events such as new protein synthesis which take time to occur.
Activation of the cascade may well be initiated after a brief
exposure to WIN55212-2 but the changes may not occur for
hours as is usual for events dependent on changes in cellular
and/or nuclear signal transduction pathways. Thus it is not
surprising that without pre-treatment, WIN55212-2 was notable to modify TNF-α induced IL-8 release. These findings are
not unique to our studies since other reports have indicated that
WIN55212-2 may require prolonged incubation with tissue to
produce its maximal effect. For instance in a study by Tyler et
al. (2000) WIN55212-2 required between 50 and 70 min to
exert maximal inhibitory effects on mucosal transport of fluids
and electrolytes across the gastrointestinal tract of the rat.
Similar observations were also made for other cannabinoids
acting on the mouse vas deferens and the myenteric plexus
preparation of guinea-pig small intestine (Pertwee et al., 1992),
and in a study on human astrocytes, WIN55212-2 was
incubated with the cells for 24 h prior to initiating induction
of NO production with IL-1-β (Sheng et al., 2005).
Previous studies showed that the IL-8 promoter contains
consensus sequences for NF-κB (Casola et al., 2002). To
determine the involvement of this transcription factor in the
regulation of TNF-α induced IL-8 release in HT-29 cells, the
profiles of activation of NF-κB was determined. Two
approaches were taken, the first being to monitor changes in
basal IκB-α levels by Western blotting and the second to
directly measure changes in NF-κB-DNA activity using
EMSAs. Under normal physiological conditions, NF-κB is
sequestrated in the cytoplasm in an inactive form as a NF-κB-
IκB complex which may be activated through phosphorylation
of the inhibitory IκB subunit by IκB kinases (IKK; Mercurio et
al., 1997; Regnier et al., 1997; Zandi et al., 1997). Phosphor-
ylation of IκB results in its ubiquitination and subsequent
degradation by the ATP-dependent proteolytic 26S proteasome
(Palombella et al., 1994) with the consequential release of NF-
κB which then translocate to the nucleus. As a result, basal
levels of IκB are usually depleted by agents that activate NF-
κB. Consistent with this notion, exposure of HT-29 cells to
TNF-α in our studies resulted in a time-dependent degradation
of the IκB-α which was relatively rapid in onset, taking
approximately 15 min to reach a maximum and remained
depleted for up to an hour before returning to the pre-stimulated
levels. This profile is consistent with the rapid but transient
activation of the NF-κB pathway due to an auto-regulatory
feedback loop that allows activated NF-κB to mediate
upregulation of IκB-α and in turn switch off any signal
production (Ghosh et al., 1998).
The decreases in IκB levels observed in our studies
correlated well with the activation of NF-κB which, once in
the nucleus, binds to its corresponding response element on the
promoter of its target gene and initiates transcription. Electro-
mobility shift assays revealed that NF-κB–DNA binding was
prominent after 10 min reaching a peak at 15 min and sustained
for up to an hour. Thus, it is clear that TNF-α may stimulate
signaling cascades that lead to the activation of NF-κB and this
may subsequently result in IL-8 release. Confirmation of this
being the case was obtained in studies employing the potent
proteasomal inhibitor MG132 which is known to block the
degradation of IκB (Palombella et al., 1994). When employed,
MG132 caused a distinct inhibition of TNF-α-induced IL-
8 release from HT-29 cells indicating that the latter process
requires activation of NF-κB. Consistent with the concept of
induced gene transcription and de novo protein synthesis are the
189M.E. Mormina et al. / European Journal of Pharmacology 540 (2006) 183–190additional data obtained with actinomycin D and with the
protein synthesis inhibitor cycloheximide. Pre-treatment with
either compound prior to stimulation with TNF-α produced a
significant inhibition of IL-8 release, indicating that the release
of IL-8 requires de novo protein synthesis and not a mere
release of the protein from pre-existing intracellular stores.
To address whether WIN55212-2 was able to suppress
induced IL-8 release through inhibition of NF-κB, studies were
carried out examining the effects of this cannabinoid on TNF-α-
induced activation of the NF-κB/IκB pathway in HT-29 cells. In
these experiments, Western blot analysis of IκB-α expression
and NF-κB–DNA binding studies showed that WIN55212-2
was able to inhibited TNF-α-induced degradation of IκB-α and
subsequently NF-κB–DNA binding. Moreover, these effects
occurred over the same concentration range that inhibited IL-
8 release and were both maximal at the highest concentrations
used (10−5 M), with significant inhibition of both processes
seen at 10−6 M WIN55212-2.
In summary, our data provide strong evidence that the
cannabinoid WIN55212-2 is able to regulate IL-8 released by
inhibiting the activation of NF-κB in HT-29 cells. This effect
may be mediated via the cannabinoid CB2 and not the CB1
receptors since our previous studies have demonstrated that
inhibition of TNF-α-induced IL-8 release by WIN55212-2
could be prevented by the potent CB2 receptor antagonist
SR144528 but not by the CB1 receptor antagonist SR141716A
(Ihenetu et al., 2003a). At present, we cannot rule out that
other novel receptors or indeed effects independent of
cannabinoid receptors may be involved in the actions of
WIN55212-2. This is particularly pertinent in light of recent
reports showing that WIN55212-2 could inhibit IL-1 signal-
ling in human astrocytes independently of cannabinoid
receptor activation (Curran et al., 2005). Although this issue
remains to be clarified, our data addressing the molecular
mechanisms for some of the immunomodulatory properties of
cannabinoids have a number of implications. Firstly our
findings contribute towards a better understanding of the
molecular mechanism of actions of cannabinoids and would
help unfold the signaling events implicated in the immune
response. Secondly, our data may provide the basis for the
development of novel therapeutic strategies that may be
beneficial in inflammatory disease states associated with the
overproduction of cytokines, including IL-8.
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